Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $168.2 million.

  • Avidity Biosciences' Non-Current Assets rose 789.67% to $168.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.2 million, marking a year-over-year increase of 789.67%. This contributed to the annual value of $21.6 million for FY2024, which is 25.26% up from last year.
  • Per Avidity Biosciences' latest filing, its Non-Current Assets stood at $168.2 million for Q3 2025, which was up 42.09% from $118.4 million recorded in Q2 2025.
  • Avidity Biosciences' 5-year Non-Current Assets high stood at $168.2 million for Q3 2025, and its period low was $2.8 million during Q1 2021.
  • Moreover, its 3-year median value for Non-Current Assets was $18.6 million (2024), whereas its average is $41.3 million.
  • Per our database at Business Quant, Avidity Biosciences' Non-Current Assets declined by 3.53% in 2022 and then spiked by 789.67% in 2025.
  • Over the past 5 years, Avidity Biosciences' Non-Current Assets (Quarterly) stood at $16.4 million in 2021, then dropped by 3.53% to $15.9 million in 2022, then increased by 8.77% to $17.2 million in 2023, then rose by 25.26% to $21.6 million in 2024, then spiked by 789.67% to $168.2 million in 2025.
  • Its Non-Current Assets stands at $168.2 million for Q3 2025, versus $118.4 million for Q2 2025 and $24.1 million for Q1 2025.